Crystalline forms
    1.
    发明授权
    Crystalline forms 有权
    结晶形式

    公开(公告)号:US07692038B2

    公开(公告)日:2010-04-06

    申请号:US11951801

    申请日:2007-12-06

    IPC分类号: C07C229/00

    CPC分类号: C07C237/22 C07B2200/13

    摘要: The present invention relates to crystalline forms of (3S)-3-[N—(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid (see formula I). The invention further relates to pharmaceutical compositions comprising such crystalline forms and to the use of said pharmaceutical compositions and said crystalline forms in the treatment of various conditions, particularly in the treatment of liver fibrosis.

    摘要翻译: 本发明涉及(3S)-3- [N-(N' - (2-叔丁基苯基)氧戊酰基)乙酰基]氨基-5-(2',3',5',6'-四氟苯氧基 )-4-氧代戊酸(参见式I)。 本发明还涉及包含这种结晶形式的药物组合物以及所述药物组合物和所述结晶形式在治疗各种病症,特别是用于治疗肝纤维化中的用途。

    CRYSTALLINE FORMS
    2.
    发明申请
    CRYSTALLINE FORMS 有权
    晶体形式

    公开(公告)号:US20080249031A1

    公开(公告)日:2008-10-09

    申请号:US11951801

    申请日:2007-12-06

    IPC分类号: A61K38/05 C07C229/36 A61P1/16

    CPC分类号: C07C237/22 C07B2200/13

    摘要: The present invention relates to crystalline forms of (3S)-3-[N—(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid (see formula I). The invention further relates to pharmaceutical compositions comprising such crystalline forms and to the use of said pharmaceutical compositions and said crystalline forms in the treatment of various conditions, particularly in the treatment of liver fibrosis.

    摘要翻译: 本发明涉及(3S)-3- [N-(N' - (2-叔丁基苯基)氧戊酰基)乙酰基]氨基-5-(2',3',5',6'-四氟苯氧基 )-4-氧代戊酸(参见式I)。 本发明还涉及包含这种结晶形式的药物组合物以及所述药物组合物和所述结晶形式在治疗各种病症,特别是用于治疗肝纤维化中的用途。

    Novel polymorphs of azabicyclohexane
    3.
    发明申请
    Novel polymorphs of azabicyclohexane 审中-公开
    氮杂双环己烷的新型多晶型物

    公开(公告)号:US20070043100A1

    公开(公告)日:2007-02-22

    申请号:US11205956

    申请日:2005-08-16

    IPC分类号: A61K31/403 C07D209/02

    摘要: The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.

    摘要翻译: 本发明提供称为多晶型A,多晶型B和多晶型C的(+) - 1-(3,4-二氯苯基)-3-氮杂双环[3.1.0]己烷的酸加成盐的多晶型,其中多晶型 形式A比其他形式更热力学稳定,制备和使用这种多晶型形式的方法和含有这种多晶型形式的药物组合物。

    Hydrocodone polymorphs
    4.
    发明申请
    Hydrocodone polymorphs 有权
    氢可酮多晶型物

    公开(公告)号:US20070072889A1

    公开(公告)日:2007-03-29

    申请号:US11371377

    申请日:2006-03-08

    申请人: Eric Hagen Aeri Park

    发明人: Eric Hagen Aeri Park

    IPC分类号: A61K31/485 C07D489/02

    CPC分类号: C07D489/02

    摘要: Hydrocodone bitartrate forms are disclosed which are useful as analgesic agents either in combination with or as replacements for hydrocodone bitartrate.

    摘要翻译: 公开了氢可酮酮酒石酸盐形式,其可用作止痛剂或与氢可酮酮酒石酸盐的组合或替代。